Drug profile · INN
cefotiam hydrochloride
CERADON
cefotiam hydrochloride (CERADON) is a bacterial penicillin-binding protein inhibitor. Associated with Takeda. Route of administration: injection. Current US regulatory status: approved.
Drug details — cefotiam hydrochloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
cefotiam hydrochloride (CERADON) is a bacterial penicillin-binding protein inhibitor. Associated with Takeda. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein inhibitor
Primary target: Bacterial penicillin-binding protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cefotiam hydrochloride?
cefotiam hydrochloride (CERADON) is a bacterial penicillin-binding protein inhibitor. Associated with Takeda. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for cefotiam hydrochloride?
CERADON is a marketed brand name for cefotiam hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cefotiam hydrochloride?
cefotiam hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.